Tvardi Therapeutics, Inc. quarterly report, Q2 FY2016

Business context and reporting period

Filing identity: The supplied filing is Cara Therapeutics, Inc.’s unaudited Form 10-Q for the quarter ended June 30, 2016—not a Tvardi Therapeutics filing. The company was a clinical-stage biopharmaceutical developer of CR845 for pain and pruritus; it had no products for sale.

Unless otherwise stated, amounts below are in U.S. dollars. Financial statement amounts are reported in thousands.

Financial performance and position

At June 30, 2016, cash and cash equivalents were $3.545 million and marketable securities were $81.219 million, totaling $84.764 million in unrestricted liquid resources. Current assets were $89.143 million; current liabilities were $8.168 million. Total assets were $92.045 million, and stockholders’ equity was $82.588 million. No debt balance is shown on the balance sheet; operating lease commitments totaled $9.467 million. The filing reports no product-sales revenue, so product gross margin is not applicable.

Material changes versus prior comparable periods

• Revenue fell 91% in Q2 and 94% in the first half, principally because prior-year collaborative revenue from deferred Maruishi license payments did not recur. 2016 clinical compound sales to Maruishi were $79,000 for Q2 and $86,000 for the half year.
• First-half R&D expense rose 139% to $19.305 million, driven primarily by later-stage CR845 trials, drug manufacturing, preclinical spending, and personnel and facility costs. General and administrative expense rose 36% to $5.092 million.
• First-half net loss increased to $23.766 million from $10.373 million; operating cash use increased to $21.292 million from $9.495 million.
• Cash and cash equivalents declined by $11.556 million in the first half. Marketable securities declined from $91.640 million at year-end 2015 to $81.219 million, while restricted cash increased from $700,000 to $1.469 million.

Outlook, management commentary, risks and unusual items

• Management estimated that cash, cash equivalents and marketable securities at June 30 would fund operations and capital needs through the end of Q1 2018, based on planned trials and excluding potential collaboration milestones. It cautioned that trial timing and costs could cause resources to be used sooner.
• Management expected expenses and losses to continue and R&D spending to increase. It also stated that additional capital would be required to meet all development objectives, particularly Oral CR845 and the uremic-pruritus program; financing may be unavailable or dilutive, and programs could be delayed, reduced or stopped.
• The Phase 3 I.V. CR845 postoperative-pain trial was placed on FDA clinical hold in February 2016 after four of 90 patients, all at the highest dose, had transient elevated sodium levels. The FDA removed the hold in April; the trial restarted in June at lower doses. Management reported no respiratory depression, Grade 1-or-higher adverse events, or CR845-associated serious adverse events in the reviewed data.
• The company had initiated a Phase 2/3 adaptive trial of I.V. CR845 for dialysis patients with uremic pruritus and planned to begin a Phase 2b Oral CR845 osteoarthritis trial in Q3 2016. These development and regulatory outcomes remained uncertain.
• The May 2016 headquarters move from Shelton to Stamford led to $899,000 of accelerated leasehold-improvement amortization for the first half and a $1.312 million Shelton lease cease-use liability, including future rent and common-area charges. Remaining Shelton lease payments were included in total lease commitments.
• Other key risks include clinical efficacy and safety, regulatory approval, manufacturing, intellectual-property protection, reimbursement, market acceptance, and the availability of financing. The company reported no material legal proceedings, no off-balance-sheet arrangements, and effective disclosure controls as of June 30, 2016.

Important facts for investors to verify

1. Confirm the issuer: the supplied text identifies Cara Therapeutics, Inc., despite request metadata naming Tvardi Therapeutics.
2. Check subsequent clinical-trial and FDA developments, including outcomes related to the sodium elevations and the revised postoperative-pain trial.
3. Assess whether the stated runway through Q1 2018 remained realistic against trial costs, enrollment timing, and the company’s stated need for additional capital.
4. Review lease-related liabilities and commitments, and distinguish restricted cash from available liquidity.
5. Track future milestone and royalty eligibility under Maruishi and CKD agreements; receipt and timing were uncertain.